Disorders of bile acids (BAs) are closely related to the development of liver and intestinal diseases, including acute pancreatitis (AP). However, the mechanism underlying the involvement of BAs in AP development remains unclear. We used intraperitoneal injection of cerulein to construct AP mouse models. These mice had significantly reduced tauroursodeoxycholic acid (TUDCA) and an imbalance of intestinal microbiota, based on 16S rDNA gene sequencing. To explore the role of AP-induced intestinal microbiota changes in the development of AP, we transplanted stool obtained from AP mice to antibiotic-treated, microbiota-depleted healthy mice. Microbiota-depleted mice presented injury to the intestinal barrier function and pancreas. Additionally, microbiota depletion reduced AP-associated pancreatic injury. This indicated that the gut microbiota may worsen AP. As TUDCA was deficient in AP mice, we gavaged AP mice with it, and evaluated subsequent expression changes in the bile acid signaling receptors farnesoid-x-receptor (FXR) and its target gene fibroblast growth factor (FGF) 15. These were downregulated, and pancreatic and intestinal barrier function injury were mitigated. Similar results were found in microbiota-depleted AP without BA treatment. However, we did not observe further downregulation of the FXR signaling pathway in microbiota-depleted AP mice given TUDCA, indicating that improvement of pancreatitis by TUDCA may be associated with gut microbiota. Our analysis of changes to the gut microbiota in AP indicated that Lactobacilli may be the key contributors.
Introduction
An important component of bile participating in fat metabolism, BAs can also act as signaling molecules by interacting with cell membranes and nuclear receptors, and play important roles in glucose and lipid metabolism and energy homeostasis [ 1 ] . Recent studies have found that dysregulated BAs are closely associated with hepatopathy, for example, steatohepatitis, hepatocellular carcinoma, and intestinal diseases such as colorectal cancer [ 2 , 3 ] . BAs circulating in the gastrointestinal tract are important messengers linking intestinal microecology and intestinal diseases. Specifically, intestinal microbes activate bile acid receptors, resulting in proportional and structural changes to bile acid composition, and thereby producing biological effects [ 4 ] . Two key receptors of BAs are the Takeda G-protein coupled receptor clone 5 (TGR5) and the farnesoid-X-Receptor (FXR) [ 1 ] . FXR is a ligand-dependent transcription factor, belonging to the nuclear receptor superfamily, and is mainly expressed in the liver, intestine, kidney, and adrenals. FXR activates fibroblast growth factor (FGF)19 in humans and FGF15 in mice [ 5 ] . Activation of bile acid receptors can further activate several specific signaling pathways including lipid metabolism, the immune system, signal transduction, and others [5] .
Acute pancreatitis (AP) is an acute digestive disease characterized by acute upper abdominal pain, elevated serum amylase, exudation of pancreatic edema, and inflammation, with a mortality rate as high as 10-30% [ 6 ] . Recent studies indicate that intestinal microbiota participate in the occurrence and development of pancreatitis [ 7 , 8 ] . Our group has previously reported dramatically changed intestinal microbiota in rats with pancreatitis, and we were able to improve the intestinal microbiota imbalance of theses rats with anti-inflammatory therapy [ 9 ] . Evidence also indicates that bile acids are involved in the development of AP, but the exact mechanisms underlying this association are unclear, especially in non-biliary pancreatitis
As gut microbiota regulates BA production and signaling, we assumed that AP-associated gut microbiota changes could result in alterations of bile acid profiles, activating bile acid-FXR-FGF15 signaling, and resulting in pancreas and intestinal injury. Therefore, we hypothesized that adjusting BA levels may treat AP. In order to study these questions, we undertook three principal experiments with murine models of AP. These examined microbiota composition and BA levels in AP, the effects of microbiota deletion and transplant, and the therapeutic effects of TUDCA supplementation.
Materials and methods

Murine AP model
This study was carried out in strict accordance with the laboratory animal management guidelines of Qingdao university, and approved by the ethics committee of Qingdao university animal experiments. Healthy male C57BL/6 mice weighing between 25 and 30 g were supplied by the Laboratory Animal Center of Qingdao University (Qingdao, China). We constructed the AP model following the method of Ding et al. Briefly, mice in the AP group were given ten hourly intraperitoneal injections of a supramaximal dose of caerulein (Sigma-Aldrich, St. Louis, Missouri, USA). Lipopolysaccharide (Sigma-Aldrich, St. Louis, Missouri, USA) was administered by intraperitoneal injection immediately after the 10 th injection of caerulein. Mice intraperitoneally injected with saline were used as controls.
Experimental 1: analysis of gut microbiota and BA levels in AP
Thirty C57BL/6 mice were randomly divided into a sham-operated group (the SO group), and an AP group, with 15 mice in each group. Mice were sacrificed at 24 h after AP induction.
Pancreatic and ileal tissues were harvested individually and fixed in 40 g/L formaldehyde.
Samples were then embedded in paraffin and continually sectioned. We collected fresh stool samples before the mice were sacrificed and stored them at -80 ℃ before subjecting them to analyses of bile acid levels and microbiota (Sections 2.2 and 2.3). Blood was collected by cardiac puncture and centrifuged at 15 000 rpm for 15 min, followed by testing for trypsin and inflammatory cytokines.
Experimental 2: effects of gut microbiota deletion and transplant
To further explore the role intestinal microbiota plays during AP, we treated healthy mice with broad-spectrum antibiotics to delete intestinal bacteria, thus creating germ-free (GF) mice. Stool samples were collected from AP mice, then transplanted to GF mice to create fecal microbiota-transplanted (FMT) mice. Further details of the GF and FMT model mice are described in Supplementary materials 1. In brief, sixty C57BL/6 mice were randomly divided into four groups of 15 as follows: an SO group, an AP group, an GF+AP group, and an GF+FMT group. Pancreatic tissues, blood, and stool samples were collected from all mice.
Experimental 3: effects of TUDCA supplementation
In the first experiment, TUDCA was found to be reduced in AP. We therefore fed AP mice a diet of standard laboratory chow supplemented with 0.4% TUDCA (Cayman Chemicals, Michigan, USA) to explore the effect of bile acid supplementation on AP. As bile acids and their conjugated forms were identified as FXR ligands, we analyzed the bile acid-FXR-FGF15 signaling axis using RT-PCR (Section 2.5). In this experiment, sixty C57BL/6 mice were randomly divided into five groups of 12 as follows: an SO group, an AP group, an AP + TUDCA pancreatitis group, a GF pancreatitis group, and a GF+ TUDCA pancreatitis group.
Analysis of intestinal microbiota
Samples were analyzed by 16S rDNA gene sequencing, the details of which we have reported previously [ 9 ] . Operational taxonomic units (OTUs) that reached 97% similarity and Shannon index were used for α -diversity estimations. Nonmetric multidimensional scaling methods were conducted to visualize differences between two groups. Linear discriminant analysis was used to explore principal differences between types of bacteria. Details of our intestinal microbiota functional annotation are given in Supplementary materials 1.
Bile acid analysis.
BA levels in feces were quantitatively measured by ultra-performance liquid chromatography triple quadrupole mass spectrometry (UPLC-TQMS) according to the following protocol.
The fecal samples were extracted with methanol and the supernatant was transferred and vacuum-dried. UPLC-MS raw data obtained with negative mode were analyzed using TargetLynx applications manager version 4.1 (Waters Corp., Milford, MA) to obtain calibration equations and the quantitative concentration of each bile acid in the samples. For details, see Supplementary materials 1.
Histological evaluation and measurement of amylase D-lactate inflammatory cytokines
Pancreas and distal ileum samples were stained with hematoxylin and eosin (HE), and examined and scored with a published system for grading of intestinal tissue injury .
Amylase activity, D-lactate level, and diamine oxidase activity in serum were measured using enzyme assay kits (Shanghai Hengfei Bioscience, China). The levels of IL-1β, TNF-α, and IL-6 were measured using an ELISA kit following the manufacturer's instructions (LMAIBio Biotech, China).
Real-time PCR analysis
Pancreatic tissue and intestinal mucosa scraped from the ileum were frozen in liquid nitrogen and stored at -80 ℃ . A standard phenol-chloroform extraction was performed to isolate total RNA from frozen tissues with Trizol reagent. Synthesis of cDNA was performed from 2μg of total RNA with a Reverse Transcription Kit (Shanghai Hengfei Bioscience, China). The real-time PCR primer sequences are listed in Supplementary materials 1.
Statistical analysis
Values are expressed as the mean ± SEM. Significant differences between two groups were evaluated with a two-tailed, software (SPSS, Chicago, IL); P<0.05 was considered statistically significant.
Results
Changes to gut microbiota and bile acid metabolism in AP mice
Acute pancreatitis was induced by intraperitoneal injections of caerulein, and was assessed based on amylase quantification and histopathological changes in pancreatic tissue.
Pancreatic inflammatory cell infiltration, hemorrhage, ileal edema, and shortened villi were observed in the AP group ( Figure 1A) . Compared with the SO group, the levels of amylase in serum were significantly increased in the AP group (P<0.05) ( Figure 1A) . The above results
indicated that the AP model was established successfully. To identify AP-induced changes to the composition of the gut microbiota, we conducted 16S rDNA amplicon sequencing. The Shannon diversity index and numbers of observed OTUs (α-diversity) of gut microbiota were remarkably decreased after AP induction ( Figure 1B ). Our nonmetric multidimensional scaling method showed that the gut microbiota composition was substantially reshaped in the AP group ( Figure 1C ). Linear discrimination analysis coupled with effect size analysis revealed significant increases of Lactobacillus and Escherichia-Shigella and substantial reductions of Roseburia, Ruminococcaceae_NK4A214_group, norank_f_Bacteroidales_ S24-7_group, and unclassified_f_Peptostreptococcaceae in AP compared with SO ( Figure   1D ). To characterize the functional alterations of the gut microbiota in AP, the relative abundances of KEGG pathways predicted by PICRUSt were calculated based on the 16S rRNA sequencing data. Multiple KEGG categories were disturbed in AP compared to SO.
There was significant enhancement of the pathways for infectious diseases, metabolism of terpenoids and polyketides, immune system diseases, and signal transduction, and significant weakening of genetic information processing, the circulatory system, transcription, and digestive system pathways ( Supplementary material 2A) .
We used UPLC-TQMS metabolite profiling to quantitate bile acid levels in the stool. The level of TUDCA was significantly decreased in the AP group ( Figure 1E ). Total bile acid levels remained unchanged, but noticeable decreases in ratios of conjugated to unconjugated BAs were observed. There was no difference in the ratio of 12α-OH to non-12α-OH bile acids (Supplementary materials 2B). Altogether, these data suggested that AP changed the gut microbiota and bile acid metabolism in mice.
AP-associated changes to the gut microbiota aggravate AP
To explore the role of AP-induced intestinal microbiota changes in the development of AP, we used four groups of mice: SO, AP, GF+AP, and GF mice given fecal transplant from AP mice (GF+FMT). Pancreatic histopathological changes were mitigated in the GF+AP group compared to the AP group (Figure 2A ). Based on plasma D-lactate and diamine oxidase levels, intestinal barrier function injury was mitigated in GF+AP (Figure 2A ). Plasma levels of TNF-α, IL-1β, and IL-6 were significantly decreased in the GF+AP group ( Figure 2B ).
Interestingly, in the GF+FMT group, mildly aggravated histology, intestinal barrier function, and plasma inflammation were found. Altogether, these data suggested that AP gut microbiota aggravate AP.
TUDCA has gut microbiome-associated therapeutic effects on AP
To explore the effect of bile acid supplementation, we gave AP mice TUDCA, in view of its . However, activation of the FXR-small heterodimer partner (SHP) inhibits bile acid synthesis. Therefore, we evaluated expression of FXR target gene mRNAs including FXR, FGF15, and SHP. We found that the intestinal FXR-FGF15 axis was downregulated with TUDCA supplementation in AP mice ( Figure 3B ). To investigate whether the gut microbiota were involved in inhibition of intestinal FXR signaling by bile acid, GF mice were used.
These mice showed downregulation of the FXR-FGF15 axis during AP, but further inhibition of FXR signaling was not observed with the addition of TUDCA ( Figure 3C ). These results revealed the involvement of the gut microbiota in inhibiting intestinal FXR signaling by TUDCA. Correlating bacterial general with TUDCA, we found positive associations for Lactobacillus (P<0.05), and some other AP-enriched bacteria including Ruminococcus 2, Prevotellaceae UCG-003, and Ruminococcus 1 (Figure 3D ). Altogether, these data suggested that TUDCA has therapeutic effects on AP associated with the gut microbiota.
Discussion
The invasion of bile acid into the pancreatic duct, caused by bile reflux, has traditionally been considered part of the pathogenesis of acute biliary pancreatitis. However, the role and mechanism of bile acid in non-biliary pancreatitis is still unclear. In this study, the level of TUDCA was reduced in mice with non-biliary pancreatitis. With TUDCA supplementation, the AP mice showed improved pancreatic and intestinal injury and decreased systemic inflammatory response. Further study indicated that a possible underlying mechanism was downregulation of bile acid-FXR-FGF15 signaling, the upregulation of which is associated with pancreatitis.
TUDCA is a nontoxic taurine conjugate form of ursodeoxycholic acid, which is an endogenously produced hydrophilic bile acid. Several studies have shown its potential for treating liver diseases [ 1 6 ] , and possible mechanisms underlying this include prevention of cell death by stabilization of the cell membranes, inhibition of apoptosis, and upregulation of survival pathways [17] . However, to our knowledge, the effects of TUDCA on AP have not been investigated previously. At present, the main AP treatments include fluid resuscitation, nutritional support, and infection prevention [ 1 8 ] . The present study indicates the potential of TUDCA as a new horizon for the treatment of AP.
In view of evidence that the gut microbiota regulate bile acid production and signaling [ 4 ] , we also investigated their relationship with AP and BAs. Our fecal transplantation experiment showed that the gut microbiota from AP mice were harmful to the intestinal function of healthy mice. Moreover, although deletion of gut microbiota and supplementation with TUDCA were both useful for the treatment of AP, our third experiment showed that deletion of gut microbiota plus TUDCA supplementation resulted in no additional therapeutic effect, with gene expression analysis revealing that gut microbiota may participate in inhibition of intestinal FXR signaling via TUDCA.
Several studies have explored the association between gut microbiota and AP by intestinal gene sequencing. Zhu et al. [ 1 4 ] found that increased capacity for bacterial invasion of epithelial cells in AP correlated closely with the abundance of Escherichia-Shigella in fecal samples from 165 adults. Zheng et al. [15] showed that commensal E. coli MG1655 increases TLR4/MyD88/p38 MAPK and ERS signaling-induced intestinal epithelial injury and aggravates AP in rats. These authors inferred gut microbiota dysbiosis in AP, and tried to explain it from different perspectives. Similar to their results, our study also found dysbiosis of the gut microbiota in AP, and the altered BA metabolism we observed is a novel potential mechanism.
The initial and major sites of injury in acute pancreatitis are the pancreas and intestines. Bile acids are critical components of the gastrointestinal tract that link the gut microbiota to hepatic and intestinal metabolism. The ability of the gut microbiota to biotransform intestinal bile acids into their unconjugated forms is central to the metabolic homeostasis of the gastrointestinal tract [ 4 ] . . In our study, disruption of bile acid-microbiota crosstalk manifested as decreases in the variety of bacterial species and their proportions, and functional alterations of the gut microbiota were reflected by decreased ratios of conjugated to unconjugated bile acids, and TUDCA deficiency. These changes were associated with further injury to the pancreas and intestines.
In a study by Sun et al. , TUDCA was confirmed as an FXR antagonist in vitro and in vivo, and our study yielded similar results.
Several limitations of this study should be addressed. Firstly, the effect of BAs on changes to the FXR-FGF 15 axis we observed need further verification with intestinal-specific Fxr knockout mice and floxed control mice, which is an aim of our future work. Secondly, we showed that Lactobacillus was positively correlated with TUDCA, but the relationships among Lactobacillus, BAs, and the FXR-FGF 15 axis during AP are unclear and deserve further study. Thirdly, we found that a significant number of bacterial species were unidentifiable because of technological limitations, and with advances in sequencing technology more gut bacteria relevant to pancreatitis may be detected.
In conclusion, BA supplementation could improve bile acid-FXR-FGF15 signaling, and reduce pancreatic and intestinal injury in AP, and this effect may be associated with the gut microbiota. It is possible that TUDCA may be a promising therapeutic treatment for AP in clinical practice. 
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